(Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
[unable to retrieve full-text content]
Purpose: Resistance to treatment with endocrine therapy in patients with HR+, HER2− advanced breast cancer (ABC) is common and dual inhibition …
Published at Tue, 13 Oct 2020 03:05:18 +0000